An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Saitama Cancer Center, Shinden

National Cancer Center Hospital, Chuo Ku

Juntendo University Hospital, Bunkyō City

Teikyo University Hospital, Itabashi-ku

Japan Anti-Tuberculosis Association Fukujuji Hospital, Kiyose-shi

The Cancer Institute Hospital of JFCR, Kōtoku

Niigata Cancer Center Hospital, Niigata

Hyogo Medical University Hospital, Nishinomiya-shi

Osaka Prefectural Hospital Organization Osaka International Cancer Institute, Osaka

Kitasato University Hospital, Sagamihara-shi

National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai

Osaka Medical and Pharmaceutical University Hospital, Takatsuki-shi

Kanagawa Cancer Center, Yokohama